Healthcare
Global Cord Blood Corporation(CORBF)
Live Price
Offline$0.95
+0.00% today
1Y Change
-36.67%
Window
Jun 25, 2025 β Jun 23, 2026
- Market Cap
- $870.00M
- Revenue Growth
- +7.2%
- EPS Growth
- -1.4%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 25, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Global Cord Blood Corporation (CORBF) is a Healthcare stock with a market cap of $870.00M and listed on OTC. The stock last traded around $0.95 and down 36.7% across the available one-year price window (Jun 25, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of -1.4%, a dividend yield of 0.0%. What stands out right now is revenue +7.2%, EPS -1.4%, free cash flow -2.6% with operating margin 49.0% and ROIC 6.3%. Valuation is more restrained than many high-expectation growth names at P/E 1.6 and price/sales 0.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CORBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.2% vs +7.6% peer median
Operating Margin
Above sector median
+49.0% vs +19.4% peer median
P/E
Below sector median
1.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2024 was reported on Apr 15, 2024, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.2% and EPS is at -1.4%, with operating margin around 49.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2024 Apr 15, 2024 | β | +0.0% | -3.3% | -63.3% |
2024 Mar 1, 2024 | β | +0.0% | -3.3% | -63.3% |
2023 Nov 14, 2023 | β | +0.0% | -3.3% | -63.3% |
Benchmark Edge
CORBF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CORBF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CORBF Max Drawdown
-88.57%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CORBF and SPY.
Company Overview
Global Cord Blood Corporation
OTC
Global Cord Blood Corporation is a healthcare company specializing in the collection, testing, processing, and storage of umbilical cord blood stem cells. Primarily serving the People's Republic of China, the company operates several cord blood banks, including facilities in key regions such as Beijing, Guangdong, and Zhejiang. These banks provide expectant parents with the option to store their newborns' cord blood for potential future medical use, leveraging advances in stem cell therapies and regenerative medicine. In addition to private storage services for subscribers, Global Cord Blood Corporation also collects and stores donated cord blood and offers matching services to patients in need of transplants, thereby supporting both individual families and public health initiatives. Founded in 2008 and headquartered in Hong Kong, the company plays a significant role in Chinaβs cord blood banking sector, contributing to the development of cellular therapies and the broader healthcare landscape through its specialized services and technical expertise.
- Leadership
- Ms. Ting Zheng
- Employees
- 1.2k
- Street Address
- Bank of China Tower, 48th Floor 1 Garden Road
- Mailing
- Central
- Region
- Central, Hong Kong
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 1.6
- EV/EBITDA
- β
- Price/Sales
- 0.7
- Price/Book
- 0.2
Growth
- Revenue
- +7.2%
- EPS
- -1.4%
- Free Cash Flow
- -2.6%
Profitability
- Gross Margin
- 85.3%
- Operating Margin
- 49.0%
- Net Margin
- 40.3%
- ROE
- 10.8%
- ROIC
- 6.3%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 10.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.